Valuation: Marker Therapeutics, Inc.

Market Cap 20.34M 17.64M 16.45M 15.12M 28.61M 1.94B 28.87M 194M 75.73M 967M 76.39M 74.71M 3.21B P/E 2026 *
-1.27x
P/E 2027 * -1.2x
Enterprise Value 20.34M 17.64M 16.45M 15.12M 28.61M 1.94B 28.87M 194M 75.73M 967M 76.39M 74.71M 3.21B EV / Sales 2026 *
7.19x
EV / Sales 2027 * 1.01x
Free-Float
94.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Marker Therapeutics, Inc.

1 day+0.82%
1 week+0.82%
Current month+8.85%
1 month-16.33%
3 months-15.75%
6 months-33.51%
Current year-17.45%
1 week 1.05
Extreme 1.05
1.31
1 month 1.05
Extreme 1.05
1.72
Current year 1.05
Extreme 1.05
2.46
1 year 0.81
Extreme 0.8099
2.46
3 years 0.81
Extreme 0.8099
6.96
5 years 0.67
Extreme 0.6706
21.7
10 years 0.67
Extreme 0.6706
135.5
Manager TitleAgeSince
Chief Executive Officer 46 2023-04-30
Chief Operating Officer 36 2023-11-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 46 2018-10-16
Chairman 65 2022-05-23
Director/Board Member 62 2019-08-05
Date Insider Type Main position Quantity % Market Cap.
11/17/25 Free

Chairman

221,741 1.7138%
11/17/25 Free

Director

221,741 1.7138%
11/17/25 Free

Director

221,741 1.7138%
Change 5-day change 1-year change 3-year change Capi.($)
+0.82%+0.82%-8.89%-78.57% 20.34M
-0.68%-0.54%-2.73%+13.55% 48.22B
+6.03%+2.87%+428.15%+506.65% 38.79B
-2.21%+7.03%+25.08%+5.51% 38.41B
+2.94%-0.89%+8.03%+56.94% 34.88B
+1.98%+3.97%+13.89%+40.90% 29.19B
+0.31%-2.42%+35.92%+122.86% 16B
+0.47%-3.48% - - 16.05B
+1.59%+2.84%+4.40%+16.88% 13.53B
-0.98%-7.07%-5.76%-37.52% 12.22B
Average +1.03%-0.55%+55.34%+71.91% 24.73B
Weighted average by Cap. +1.21%+0.21%+80.81%+109.97%

Financials

2026 *2027 *
Net sales 2.83M 2.45M 2.29M 2.1M 3.98M 270M 4.02M 26.93M 10.54M 135M 10.63M 10.4M 446M 20.09M 17.42M 16.25M 14.93M 28.25M 1.92B 28.51M 191M 74.78M 955M 75.43M 73.77M 3.17B
Net income -19.36M -16.79M -15.66M -14.39M -27.23M -1.85B -27.48M -184M -72.09M -921M -72.71M -71.11M -3.05B -19.89M -17.25M -16.09M -14.79M -27.98M -1.9B -28.23M -189M -74.06M -946M -74.71M -73.06M -3.14B
Net Debt - -
Logo Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Employees
5
Date Price Change Volume
26-08-04 US$1.230 +0.82% 30,849
26-08-03 US$1.220 +7.96% 65,431
26-07-31 US$1.130 +0.89% 37,439
26-07-30 US$1.120 +0.90% 72,944
26-07-29 US$1.110 -5.93% 39,225
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.230USD
Average target price
7.867USD
Spread / Average Target
+539.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRKR Stock